We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed at $27.41 in the latest trading session, marking a +1.59% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.25%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.03%.
Prior to today's trading, shares of the drugmaker had lost 5.43% over the past month. This has lagged the Medical sector's gain of 0.11% and the S&P 500's gain of 3.34% in that time.
The investment community will be closely monitoring the performance of Pfizer in its forthcoming earnings report. The company's upcoming EPS is projected at $0.45, signifying a 32.84% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $13.21 billion, reflecting a 3.72% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.38 per share and a revenue of $60.66 billion, signifying shifts of +29.35% and +3.7%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Pfizer. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.63% lower. Currently, Pfizer is carrying a Zacks Rank of #3 (Hold).
Investors should also note Pfizer's current valuation metrics, including its Forward P/E ratio of 11.36. Its industry sports an average Forward P/E of 14.43, so one might conclude that Pfizer is trading at a discount comparatively.
We can also see that PFE currently has a PEG ratio of 1.06. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.78 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 156, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Pfizer (PFE - Free Report) closed at $27.41 in the latest trading session, marking a +1.59% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.25%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.03%.
Prior to today's trading, shares of the drugmaker had lost 5.43% over the past month. This has lagged the Medical sector's gain of 0.11% and the S&P 500's gain of 3.34% in that time.
The investment community will be closely monitoring the performance of Pfizer in its forthcoming earnings report. The company's upcoming EPS is projected at $0.45, signifying a 32.84% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $13.21 billion, reflecting a 3.72% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.38 per share and a revenue of $60.66 billion, signifying shifts of +29.35% and +3.7%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Pfizer. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.63% lower. Currently, Pfizer is carrying a Zacks Rank of #3 (Hold).
Investors should also note Pfizer's current valuation metrics, including its Forward P/E ratio of 11.36. Its industry sports an average Forward P/E of 14.43, so one might conclude that Pfizer is trading at a discount comparatively.
We can also see that PFE currently has a PEG ratio of 1.06. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.78 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 156, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.